在930例未行前哨淋巴结活检的临床I/II期黑色素瘤患者独立队列中使用Merlin检测(CP-GEP)进行风险分层
该研究纳入2000至2020年德国图宾根大学930例未行前哨淋巴结活检的临床I/II期皮肤黑色素瘤患者,用Merlin检测(CP-GEP)分为高风险与低风险。CP-GEP低风险组879例、高风险组51例,低风险组10年无复发生存、无远处转移生存和黑色素瘤特异性生存均显著优于高风险组,且检测性能不受组织学亚型影响。
要点
- CP-GEP低风险879例,高风险51例。
- 低风险组10年RFS的HR为20.07(p<0.001)。
- 低风险组10年DMFS的HR为19.39(p<0.001)。
核心结论
- CP-GEP有潜力对未行前哨淋巴结活检的早期黑色素瘤患者进行复发风险分层。
- CP-GEP低风险患者长期生存显著更好。
- CP-GEP在指导前哨淋巴结活检转诊方面有前景,并可能通过优化个体化治疗方案和潜在监测方案支持黑色素瘤诊疗。
研究设计与样本
- 分析2000年至2020年德国图宾根大学930例临床I/II期原发性皮肤黑色素瘤患者,均未行前哨淋巴结活检。
- Merlin检测(CP-GEP)结合诊断时年龄、Breslow厚度和原发肿瘤8个特定基因的基因表达,输出高风险和低风险标签。
主要发现
- CP-GEP将879例归为低风险、51例归为高风险。
- 10年无复发生存(RFS)在CP-GEP低风险组较高风险组显著更高(HR 20.07;p<0.001)。
- 10年无远处转移生存(DMFS)在CP-GEP低风险组较高风险组显著更高(HR 19.39;p<0.001)。
- 10年黑色素瘤特异性生存(MSS)在CP-GEP低风险组较高风险组显著更高(HR 35.85;p<0.001)。
- 在恶性雀斑样黑色素瘤和肢端雀斑样黑色素瘤中,CP-GEP检测性能不受黑色素瘤组织学亚型影响。
关键数值与推荐
- CP-GEP风险输出标签为高风险和低风险。
- CP-GEP低风险组10年RFS的HR为20.07(p<0.001),高风险组为参照。
- CP-GEP低风险组10年DMFS的HR为19.39(p<0.001),高风险组为参照。
- CP-GEP低风险组10年MSS的HR为35.85(p<0.001),高风险组为参照。
临床怎么用
- CP-GEP有潜力对未行前哨淋巴结活检的早期黑色素瘤患者进行复发风险分层。
- CP-GEP在指导前哨淋巴结活检转诊方面有前景,并可能支持通过优化个体化治疗方案和潜在监测方案改善黑色素瘤诊疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: More than 80 % of patients with melanoma are diagnosed without nodal metastasis, but most of those who relapse or die from melanoma are initially diagnosed as low risk early-stage. Here we investigate the ability of the Merlin Assay to stratify patients who did not undergo sentinel lymph node biopsy (SLNB) for their risk of recurrence. PATIENTS AND METHODS: 930 patients with clinical stage I/II primary cutaneous melanoma from the University of Tuebingen diagnosed between 2000 and 2020 were analyzed. None of the patients included underwent SLNB. The Merlin Assay combines patient age at diagnosis, Breslow thickness, and gene expression of eight specific genes from the primary tumor. Risk output labels are High Risk and Low Risk. RESULTS: Clinicopathological gene expression profile (CP-GEP) identified 879 patients as Low Risk and 51 patients as High Risk. The 10-year RFS (HR 20.07; p < 0.001) and DMFS (HR 19.39; p < 0.001) were significantly higher in CP-GEP Low Risk versus High Risk patients. Similar results were observed in 10-year MSS (HR 35.85; p < 0.001). CP-GEP analysis of lentigo maligna melanoma and acral lentiginous melanoma showed that the performance of assay was independent of melanoma histological subtypes. CONCLUSION: This study shows that CP-GEP has the potential to stratify patients with early-stage melanoma who did not undergo SLNB based on their risk of recurrence. Patients with CP-GEP Low Risk have a significantly better long-term survival. CP-GEP shows to be promising for guiding SLNB referral and may support melanoma care by optimizing personalized treatment plans and potential surveillance regimens.
引用
- Amaral T, Chatziioannou E, Nuebling A, et al. Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy. Eur J Cancer. 2025. PMID: 40274320. doi:10.1016/j.ejca.2025.115372
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。